Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapiesVelia Chiara Di Maio, Francesca Ceccherini‐Silberstein, Valeria Cento et al.|Liver International|2017Cited by 90
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?Velia Chiara Di Maio, L. Lambiase, Massimo Andreoni et al.|Journal of Hepatology|2017Cited by 31
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levelsVelia Chiara Di Maio, Valeria Cento, M. Aragri et al.|Journal of Antimicrobial Chemotherapy|2015Cited by 13
Multiclass hepatitis C virus resistance to direct acting antivirals in real life interferon-free regimens failures advocates for tailored second-line therapiesVelia Chiara Di Maio, M. Paoloni, Valeria Cento et al.|Journal of Hepatology|2017Cited by 2
VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimenVelia Chiara Di Maio, Sergio Babudieri, M. Aragri et al.|Digestive and Liver Disease|2020Cited by 1